Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-10-18 3:31 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | 6,191,937 5.100% | 6,191,937 (New Position) | View | |
| 2024-02-14 5:18 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | EcoR1 Capital LLC | 11,173,068 9.400% | 4,865,521 (+77.14%) | View |
| 2024-02-14 10:04 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | T. Rowe Price Investment Management Inc. | 6,303,584 5.300% | 460,924 (+7.89%) | View |
| 2024-02-14 09:23 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | Avoro Capital Advisors LLC | 13,411,111 9.900% | 2,786,111 (+26.22%) | View |
| 2024-02-13 4:58 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | VANGUARD GROUP INC | 9,555,678 8.060% | 343,187 (+3.73%) | View |
| 2024-02-08 10:05 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 16,477,850 13.910% | 1,706,991 (+11.56%) | View |
| 2023-09-08 10:29 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 14,770,859 12.550% | 5,950,461 (+67.46%) | View |
| 2023-07-18 5:16 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | EcoR1 Capital LLC | 6,307,547 5.400% | 6,307,547 (New Position) | View |
| 2023-07-07 4:35 pm Sale | 13G | Apellis Pharmaceuticals Inc. APLS | BlackRock Inc. BLK | 5,747,184 4.900% | -1,957,010 (-25.40%) | View |
| 2023-02-14 12:40 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | T. Rowe Price Investment Management Inc. | 5,842,660 5.300% | 5,842,660 (New Position) | View |
| 2023-02-14 12:38 pm Sale | 13G | Apellis Pharmaceuticals Inc. APLS | PRICE T ROWE ASSOCIATES INC | 2,749,542 2.500% | -2,557,944 (-48.20%) | View |
| 2023-02-14 09:36 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | Avoro Capital Advisors LLC | 10,625,000 9.600% | 2,069,445 (+24.19%) | View |
| 2023-02-09 11:07 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | VANGUARD GROUP INC | 9,212,491 8.330% | 1,295,392 (+16.36%) | View |
| 2023-02-06 2:49 pm Sale | 13G | Apellis Pharmaceuticals Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 8,820,398 7.980% | -3,657,855 (-29.31%) | View |
| 2023-01-31 5:52 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | BlackRock Inc. BLK | 7,704,194 7.000% | 1,838,482 (+31.34%) | View |
| 2022-02-14 4:05 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | Morningside Venture Investments Ltd | 12,806,342 13.200% | 250,000 (+1.99%) | View |
| 2022-02-14 4:04 pm Sale | 13G | Apellis Pharmaceuticals Inc. APLS | HHLR ADVISORS LTD. | 0 0.000% | -5,028,289 (Position Closed) | View |
| 2022-02-14 2:34 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | PRICE T ROWE ASSOCIATES INC | 5,307,486 5.400% | 5,307,486 (New Position) | View |
| 2022-02-11 10:04 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | Avoro Capital Advisors LLC | 8,555,555 8.900% | 8,555,555 (New Position) | View |
| 2022-02-09 3:24 pm Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | VANGUARD GROUP INC | 7,917,099 8.140% | 2,375,274 (+42.86%) | View |